By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Ophthalmic steroids with anti-infectives > Loteprednol and tobramycin (ophthalmic) > Loteprednol / Tobramycin Ophthalmic Dosage
Ophthalmic steroids with anti-infectives
https://themeditary.com/dosage-information/loteprednol-tobramycin-ophthalmic-dosage-9462.html

Loteprednol / Tobramycin Ophthalmic Dosage

Drug Detail:Loteprednol and tobramycin (ophthalmic) (Loteprednol and tobramycin (ophthalmic) [ loe-te-pred-nol-and-toe-bra-mye-sin-off-thal-mik ])

Drug Class: Ophthalmic steroids with anti-infectives

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Uveitis

Apply 1 or 2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; during the initial 24 to 48 hours, may increase frequency to every 1 to 2 hours

Comments:

  • The frequency should be gradually decreased as warranted by improvement of clinical signs.
  • Care should be taken as to not discontinue therapy prematurely.
  • A maximum of 20 mL should be prescribed initially and not refilled without further evaluation.

Use: For the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists; the anti-infective component of this drug is active against the following common bacterial eye pathogens: Staphylococcus aureus, S epidermidis (coagulase positive and negative), some Group A beta-hemolytic and some nonhemolytic streptococci, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, H aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus, Klebsiella pneumoniae, and some Neisseria species

Usual Adult Dose for Iritis

Apply 1 or 2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; during the initial 24 to 48 hours, may increase frequency to every 1 to 2 hours

Comments:

  • The frequency should be gradually decreased as warranted by improvement of clinical signs.
  • Care should be taken as to not discontinue therapy prematurely.
  • A maximum of 20 mL should be prescribed initially and not refilled without further evaluation.

Use: For the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists; the anti-infective component of this drug is active against the following common bacterial eye pathogens: Staphylococcus aureus, S epidermidis (coagulase positive and negative), some Group A beta-hemolytic and some nonhemolytic streptococci, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, H aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus, Klebsiella pneumoniae, and some Neisseria species

Usual Adult Dose for Ocular Infection

Apply 1 or 2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; during the initial 24 to 48 hours, may increase frequency to every 1 to 2 hours

Comments:

  • The frequency should be gradually decreased as warranted by improvement of clinical signs.
  • Care should be taken as to not discontinue therapy prematurely.
  • A maximum of 20 mL should be prescribed initially and not refilled without further evaluation.

Use: For the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists; the anti-infective component of this drug is active against the following common bacterial eye pathogens: Staphylococcus aureus, S epidermidis (coagulase positive and negative), some Group A beta-hemolytic and some nonhemolytic streptococci, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, H aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus, Klebsiella pneumoniae, and some Neisseria species

Usual Adult Dose for Allergic Conjunctivitis

Apply 1 or 2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; during the initial 24 to 48 hours, may increase frequency to every 1 to 2 hours

Comments:

  • The frequency should be gradually decreased as warranted by improvement of clinical signs.
  • Care should be taken as to not discontinue therapy prematurely.
  • A maximum of 20 mL should be prescribed initially and not refilled without further evaluation.

Use: For the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists; the anti-infective component of this drug is active against the following common bacterial eye pathogens: Staphylococcus aureus, S epidermidis (coagulase positive and negative), some Group A beta-hemolytic and some nonhemolytic streptococci, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, H aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus, Klebsiella pneumoniae, and some Neisseria species

Usual Adult Dose for Bacterial Conjunctivitis

Apply 1 or 2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; during the initial 24 to 48 hours, may increase frequency to every 1 to 2 hours

Comments:

  • The frequency should be gradually decreased as warranted by improvement of clinical signs.
  • Care should be taken as to not discontinue therapy prematurely.
  • A maximum of 20 mL should be prescribed initially and not refilled without further evaluation.

Use: For the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists; the anti-infective component of this drug is active against the following common bacterial eye pathogens: Staphylococcus aureus, S epidermidis (coagulase positive and negative), some Group A beta-hemolytic and some nonhemolytic streptococci, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, H aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus, Klebsiella pneumoniae, and some Neisseria species

Usual Adult Dose for Keratitis

Apply 1 or 2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; during the initial 24 to 48 hours, may increase frequency to every 1 to 2 hours

Comments:

  • The frequency should be gradually decreased as warranted by improvement of clinical signs.
  • Care should be taken as to not discontinue therapy prematurely.
  • A maximum of 20 mL should be prescribed initially and not refilled without further evaluation.

Use: For the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists; the anti-infective component of this drug is active against the following common bacterial eye pathogens: Staphylococcus aureus, S epidermidis (coagulase positive and negative), some Group A beta-hemolytic and some nonhemolytic streptococci, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, H aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus, Klebsiella pneumoniae, and some Neisseria species

Usual Adult Dose for Cyclitis

Apply 1 or 2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; during the initial 24 to 48 hours, may increase frequency to every 1 to 2 hours

Comments:

  • The frequency should be gradually decreased as warranted by improvement of clinical signs.
  • Care should be taken as to not discontinue therapy prematurely.
  • A maximum of 20 mL should be prescribed initially and not refilled without further evaluation.

Use: For the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists; the anti-infective component of this drug is active against the following common bacterial eye pathogens: Staphylococcus aureus, S epidermidis (coagulase positive and negative), some Group A beta-hemolytic and some nonhemolytic streptococci, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, H aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus, Klebsiella pneumoniae, and some Neisseria species

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • For ophthalmic use only.
  • Shake well before use.

Storage requirements:
  • Store upright.
  • Protect from freezing.

Monitoring:
  • Ocular: Routinely measure intraocular pressure if this drug is used for 10 days or longer.

Patient advice:
  • Avoid allowing the tip of the dropper to touch any surface as this may contaminate the suspension.
  • If pain develops, redness, itching, or inflammation becomes aggravated, consult a physician.
  • Avoid wearing soft contact lenses when using this drug.
Share this Article
Latest News
Medical News

Type 2 diabetes: Sugary drinks may significantly raise risk

May 30, 2025
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Ministrokes may result in 1 year of chronic fatigue
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by